Key Documents
Willard ("Bill") E. Fee, Jr.
Academic Appointments
- Professor, Otolaryngology (Head and Neck Surgery)
- Member, Cancer Center
Contact Information
-
Clinical Offices
Otolaryngology - Head/Neck Surgery 875 Blake Wilbur Dr Clinic B Stanford, CA 94305-5820 Tel Work (650) 498-6000 Fax (650) 736-7691
-
Academic Offices
Personal Information Email Tel (650) 725-6500Not for medical emergencies or patient use
Professional Snapshot
Clinical Focus
- Cancer > Head and Neck Cancer
- Otolaryngology
- Head and Neck Tumor Surgery
- Nasopharyngeal Cancer
- Otolaryngology/Head&Neck
Professional Education
| Board Certification: | Otolaryngology, American Board of Otolaryngology (1974) |
| Residency: | UCLA Medical Center, CA (1974) |
| Residency: | Wadsworth General Hospital - VA, CA (1971) |
| Internship: | Harbor-UCLA Medical Center, CA (1970) |
| Medical Education: | University of Colorado School of Medicine, CO (1969) |
Community & International Work
Scientific Focus
Research Interests
IRX-2 is a biologic product containing multiple ultra low dose cytokines (IL-1 beta. IL:=2,6,8,10,12, TNF- alpha, G-CSF, and GM-CSF) produced from PHA stimulated monoclear cells obtain from normal donors. Cyclophosphamide 300mg/m2 is given IV on day 1, indomethacin 25 mg p.o. tid together with oral zinc and multivitamins are given daily for 3 weeks. 1cc of IRX-2 is given into each upper sternocleidomasatoid muscle for 10 days between days 4 and 15 (not on Saturday and Sunday). Mutivitamin Supplement and Zinc will also be given. Safety and freedom from relapse will be measured for 5 years.
Clinical Trials
- Biopsy of human tumors for cancer stem cell characterization: a feasibility study Recruiting
- Identification and Characterization of Novel Proteins in Head and Neck Cancer Recruiting
- A Phase 2 Clinical Trial of the Effectiveness of IRX-2 in Treating Patients With Operable Head and Neck Cancer No longer recruiting
- Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation No longer recruiting
Publications
- Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2008; (2): 393-400
- Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma. Head Neck. 2007; (3): 211-20
- Quality of life 17 to 20 years after uvulopalatopharyngoplasty. Laryngoscope. 2007; (3): 503-6
- Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas. Cancer. 2006; (9): 1940-9
- Advanced-staged tonsillar squamous carcinoma: organ preservation versus surgical management of the primary site. Head Neck. 2006; (7): 587-94

